Trabectedin 中文名称: 他比特定

别名: Trabectedin; ET-743; ET 743; 114899-77-3; Yondelis; Ecteinascidin; ecteinascidin 743; ET743; Ecteinascidin 743 曲贝替定;他比特啶;他比特定;TRABECTEDIN曲贝替定

目录号: V16679 纯度: ≥98%

COA 产品数据产品说明书 SDS

Trabectedin (ET743; Ecteinascidin-743; ET-743; 商品名 Yondelis) 是一种新型海洋来源抗肿瘤药物，具有有效的体外和体内抗肿瘤活性。

Trabectedin CAS号: 114899-77-3
产品类别: Apoptosis

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
1mg
5mg
10mg
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

Other Forms of Trabectedin:

Trabectedin-d3 (Ecteinascidin 743-d3; ET-743-d3)

点击了解更多

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

纯度/质量控制文件

批次：

纯度: =99.84%

COA

MSDS

NMR

HPLC

产品说明书

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息
相关产品

产品描述

Trabectedin（也称为 ET743；Ecteinascidin-743；ET-743；商品名 Yondelis）是一种新型海洋来源抗肿瘤药物，具有有效的体外和体内抗肿瘤活性。截至2015年，它已被授权作为抗肿瘤化疗药物，用于治疗卵巢癌和晚期软组织肉瘤。在两种类型的乳腺癌细胞中，曲贝替定以时间和浓度依赖性方式引起细胞毒性和细胞凋亡。
Trabectdin是一种四氢异喹啉生物碱，从加勒比海的Ecteinascidia turbinata中提取。用于治疗软组织肉瘤和复发性卵巢癌症。它具有抗肿瘤剂、海洋代谢物、抗炎剂、血管生成调节剂和烷化剂的作用。它是一种有机杂环化合物、氮杂螺化合物、恶螺化合物、桥联化合物、内酯、多酚、乙酸酯、半氨基、有机硫化物、叔氨基化合物和异喹啉生物碱。
Trabectdin，在其开发过程中也被称为ET-743，是一种海洋衍生的抗肿瘤药物，发现于Carribean外壳Ecteinascidia turbinata中，现在可以合成生产。Trabectdin具有独特的作用机制。它与DNA的小凹槽结合，干扰细胞分裂和遗传转录过程以及DNA修复机制。它已被批准在欧洲、俄罗斯和韩国用于治疗晚期软组织肉瘤。它目前正在评估用于治疗乳腺癌症、癌症以及儿童肉瘤。欧盟委员会和美国食品药品监督管理局（FDA）都已批准曲贝替丁作为软组织肉瘤和卵巢癌症的孤儿药。2015年10月23日，美国食品药品监督管理局批准trabectedin（即Yondelis）用于治疗特定的软组织肉瘤。
曲贝替丁是一种烷基化药物。trabectedin的作用机制是作为烷基化活性。
Trabectdin是一种来自加勒比海海鞘的天然产物，具有抗肿瘤活性，用于治疗软组织肉瘤。小梁特丁治疗与治疗期间短暂的血清酶升高率高以及偶尔出现临床明显的肝损伤伴黄疸有关。
已有报道称，Trabectdin存在于鼻甲外鞘中。
Trabectdin是一种四氢异喹啉生物碱，从海洋被膜Ecteinascidia turbinata中分离出来，具有潜在的抗肿瘤活性。trabectedin与DNA的小凹槽结合，干扰转录偶联核苷酸切除修复机制，诱导致命的DNA链断裂，并阻断G2期的细胞周期。
TRABECTEDIN是一种小分子药物，其最大临床试验阶段为IV（所有适应症），于2007年首次获得批准，有10个批准的适应症和16个研究适应症。
一种复杂的结构，包括由环酯连接的异喹啉；它是一种DNA结合剂和鸟嘌呤N2烷基化剂，来源于海洋被膜，鼻甲外鞘。曲贝替丁用于治疗蒽环类或异环磷酰胺药物治疗失败后的晚期软组织严重急性呼吸系统综合征。

生物活性&实验参考方法

靶点	MX-1 cells (IC50 = 0.1 nM); MCF7 cells (IC50 = 1.5 nM); MCF7/DXR cells (IC50 = 3.7 nM); Reactive oxygen species (ROS); Apoptosis Trabectedin binds to the minor groove of DNA, particularly guanine-rich sequences, and functions as a DNA alkylating agent [2] Trabectedin exhibits anti-proliferative activity in MCF-7 cells (IC50 = 1.5 nM) and MDA-MB-453 cells [2]
体外研究 (In Vitro)	使用曲贝替定（ET-743；10 nM；24-72 小时；MCF7 细胞）处理会导致细胞在 S 期晚期至 G2 期积累[1]。 Trabectedin 的 IC50 分别为 0.1 nM、1.5 nM 和 3.7 nM，抑制 MX-1、MCF7 和 MCF7/DXR 细胞的生长[1]。曲贝替定在两种类型的乳腺癌细胞中引起细胞毒性和细胞凋亡，其方式取决于时间和浓度。当曲贝替定应用于MCF-7细胞时，死亡受体途径分子TRAIL-R1/DR4、TRAIL-R2/DR5、FAS/TNFRSF6、TNF RI/TNFRSF1A和FADD的表达水平显着增加2.6、3.1、分别是 1.7、11.2 和 4.0 倍。 MDA-MB-453 细胞中促凋亡蛋白 Bax、Bad、细胞色素 c、Smac/DIABLO 和 cleaved Caspase-3 表达水平增加 4.2、3.6、4.8、4.5 和 4.4 倍，而抗凋亡蛋白表达增加Bcl-2 和 Bcl-XL 水平降低 4.8 倍和 5.2 倍[2]。当在体外用非细胞毒性浓度的曲贝替定处理时，粘液样脂肪肉瘤 (MLS) 原代肿瘤培养物和/或细胞系可以产生 CCL2、CXCL8、IL-6、VEGF 和 PTX3[3]。在人乳腺癌细胞系中，曲贝替定（ET-743）与NSC 125973联合使用时表现出序列依赖性协同细胞毒性。与单药治疗相比，联合用药增强了细胞生长抑制作用，当曲贝替定先于NSC 125973给药时协同效应最强[1] 在MCF-7（HER2-/ER+）细胞中，曲贝替定通过上调死亡受体通路分子诱导凋亡：TRAIL-R1/DR4（2.6倍）、TRAIL-R2/DR5（3.1倍）、FAS/TNFRSF6（1.7倍）、TNF RI/TNFRSF1A（11.2倍）和FADD（4.0倍）。在MDA-MB-453（HER2+/ER-）细胞中，其通过增加促凋亡蛋白Bax（4.2倍）、Bad（3.6倍）、细胞色素c（4.8倍）、Smac/DIABLO（4.5倍）和 cleaved caspase-3（4.4倍）激活线粒体通路，同时降低抗凋亡蛋白Bcl-2（4.8倍）和Bcl-XL（5.2倍）。两种细胞系中活性氧（ROS）生成均增加[2] 在人黏液样脂肪肉瘤（MLS）细胞中，非细胞毒性浓度的曲贝替定选择性抑制促炎因子（CCL2、CXCL8、IL-6）、VEGF和PTX3的产生[3]
体内研究 (In Vivo)	使用曲贝汀（ET-743；30-50 μg/kg；静脉注射；每三天；雌性无胸腺裸鼠）治疗可增加携带 MX-1 乳腺癌异种移植物的裸鼠的抗肿瘤作用，而不增加毒性[1]。曲贝替定治疗后，在人粘液样脂肪肉瘤 (MLS) 异种移植小鼠模型中，CCL2、CXCL8、CD68+ 浸润巨噬细胞、CD31+ 肿瘤血管和 PTX3 部分减少显着减少[3]。在人乳腺癌异种移植小鼠模型中，曲贝替定单药抑制肿瘤生长，与NSC 125973联合使用时以序列依赖性方式进一步减小肿瘤体积（曲贝替定先给药时效果更优）[1] 在人MLS异种移植模型中，曲贝替定处理显著减少CCL2、CXCL8、CD68+浸润巨噬细胞和CD31+肿瘤血管，PTX3部分降低[3]
细胞实验	乳腺癌细胞接种于培养板中，以不同浓度和序列单独或联合使用曲贝替定与NSC 125973处理。采用标准细胞毒性试验评估细胞活力，通过联合指数计算分析协同作用[1] MCF-7和MDA-MB-453细胞暴露于0.1–100 nM 曲贝替定 24–72小时。通过流式细胞术检测凋亡，通过蛋白质印迹法测定细胞裂解物中蛋白表达水平[2] MLS原代培养物和细胞系用非细胞毒性剂量的曲贝替定处理。通过免疫测定量化培养上清液中的细胞因子和生长因子水平（CCL2、CXCL8、IL-6、VEGF、PTX3）[3] 在收集样品进行蛋白质印迹分析之前，将 RNAiMax Lipofectamine（6 孔培养皿中每孔 4.5 mL）添加到靶向 EWS-FLI1 断点位点 II 的 siRNA 中，与细胞复合、结合，并孵育 36 至 48 小时。
动物实验	携带人乳腺癌异种移植瘤的雌性裸鼠被随机分为三组，分别接受曲贝替定（剂量未指定）、NSC 125973 或二者联合治疗，治疗顺序各不相同。药物通过静脉注射给药，每周测量两次肿瘤体积[1]。携带MLS异种移植瘤的裸鼠接受曲贝替定（剂量未指定）静脉注射治疗。治疗后收集肿瘤组织，通过免疫组织化学方法评估细胞因子水平、巨噬细胞浸润和血管密度[3]。
药代性质 (ADME/PK)	吸收、分布和排泄静脉给药。生物半衰期 33-50 小时
毒性/毒理 (Toxicokinetics/TK)	肝毒性几乎所有接受曲贝替定治疗的患者都会出现血清转氨酶水平升高，其中20%至50%的患者转氨酶水平超过正常值上限5倍以上。地塞米松预处理似乎可以降低酶升高的程度和频率。酶升高通常在静脉输注后2至5天内出现，在5至9天达到峰值，并在3至4周内通常降至基线水平。血清碱性磷酸酶和胆红素轻度升高也很常见。然而，曲贝替定引起的临床上明显的肝损伤（伴有黄疸）较为罕见。另一方面，患有基础肝病的患者发生败血症和多器官功能衰竭的风险似乎更高，因此建议在治疗前和治疗期间监测肝功能。肝损伤通常类似于基础肝硬化的急性失代偿，表现为血清酶轻度升高、黄疸加重和肝脏合成功能障碍。免疫过敏和自身免疫特征不常见。死亡通常由脓毒症和多器官功能衰竭引起。可能性评分：C[HD]（临床上明显的肝损伤的可能原因，通常发生在既往存在肝病和使用高剂量药物的情况下）。蛋白结合率 94%至98%
参考文献	[1]. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and NSC 125973 in human breast cancer cell linesin vitro and in vivo. Cancer Res. 2002 Dec 1;62(23):6909-15. [2]. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013 Jun 20;221(2):128-136. [3]. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235-44.
其他信息	曲贝替定（ET-743；Ecteinascidin-743）是一种海洋来源的四氢异喹啉生物碱，具有抗肿瘤活性[2][3] 曲贝替定和NSC 125973在乳腺癌细胞中的协同作用具有序列依赖性，这可能是由于它们对DNA损伤修复途径的不同影响所致[1] 在MLS细胞中，曲贝替定既具有直接的抗肿瘤作用，又具有间接的抗炎/抗血管生成活性[3] 1. 药物来源和结构：曲贝替定（ET743；Ecteinascidin-743）是一种半合成的四氢异喹啉生物碱，最初是从海洋被囊动物Ecteinascidia turbinata中分离得到的。其化学结构使其能够特异性地与 DNA 小沟结合，这是其抗肿瘤活性的基础[2] 2. 凋亡机制特异性：曲贝替定（ET743；Ecteinascidin-743）以基因型依赖的方式诱导乳腺癌细胞凋亡：它激活 HER2-/ER+ MCF-7 细胞中的外源性死亡受体途径和 HER2+/ER- MDA-MB-453 细胞中的内源性线粒体途径。这种特异性提示了基于肿瘤分子亚型的潜在个体化治疗策略[2] 3. 抗炎机制假说：曲贝替定（ET743；Ecteinascidin-743）在人黏液样脂肪肉瘤细胞中的抗炎作用可能通过抑制NF-κB信号通路（通过减少p65核转位）介导，从而抑制促肿瘤炎症微环境，进而增强其整体抗肿瘤活性[3] 4. 联合治疗意义：曲贝替定（ET743；Ecteinascidin-743）和NSC 125973在乳腺癌模型中的顺序依赖性协同作用凸显了联合治疗方案中用药顺序的重要性，这可能指导涉及曲贝替定的联合疗法的临床试验设计[1] 药效学该药物结构中的两个环使其能够它与DNA的小沟共价结合。第三个环从DNA中突出，使其能够与附近的核蛋白相互作用。这种相互作用会产生叠加效应，从而阻断细胞在G2期的分裂。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C39H43N3O11S
分子量	761.843
精确质量	761.261
元素分析	C, 61.49; H, 5.69; N, 5.52; O, 23.10; S, 4.21
CAS号	114899-77-3
相关CAS号	Trabectedin-d3
PubChem CID	108150
外观&性状	White to light yellow solid powder
密度	1.6±0.1 g/cm3
折射率	1.732
LogP	3.1
tPSA	194.02
氢键供体(HBD)数目	4
氢键受体(HBA)数目	15
可旋转键数目(RBC)	4
重原子数目	54
分子复杂度/Complexity	1450
定义原子立体中心数目	7
SMILES	CC1=C(OCO2)C2=C([C@H](COC3=O)N4[C@]([C@@H]5SC[C@]63C(C=C(OC)C(O)=C7)=C7CCN6)([H])[C@@H]8N(C)[C@@H](CC9=CC(C)=C(OC)C(O)=C98)[C@@H]4O)C5=C1OC(C)=O
InChi Key	PKVRCIRHQMSYJX-RJZIEWFPSA-N
InChi Code	InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1
化学名	[(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
别名	Trabectedin; ET-743; ET 743; 114899-77-3; Yondelis; Ecteinascidin; ecteinascidin 743; ET743; Ecteinascidin 743
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意： (1). 本产品在运输和储存过程中需避光。 (2). 请将本产品存放在密封且受保护的环境中（例如氮气保护），避免吸湿/受潮。 (3). 该产品在溶液状态不稳定，请现配现用。
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	DMSO: 33.3~100 mg/mL (43.8~131.3 mM)
溶解度 (体内实验)	配方 1 中的溶解度: ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。 20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。配方 2 中的溶解度:* ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。 View More 配方 3 中的溶解度: ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。 *生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

DMSO: 33.3~100 mg/mL (43.8~131.3 mM)

溶解度 (体内实验)

配方 1 中的溶解度: ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

配方 2 中的溶解度: ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (3.28 mM) (饱和度未知) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	1.3126 mL	6.5631 mL	13.1261 mL
	5 mM	0.2625 mL	1.3126 mL	2.6252 mL
	10 mM	0.1313 mL	0.6563 mL	1.3126 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
CTID: NCT06524583
Phase: Phase 2 Status: Not yet recruiting
Date: 2024-12-02

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
CTID: NCT05432791
Phase: Phase 2/Phase 3 Status: Active, not recruiting
Date: 2024-11-12

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
CTID: NCT06263231
Phase: Phase 3 Status: Recruiting
Date: 2024-11-04

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
CTID: NCT04076579
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-07-29

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
CTID: NCT04383119
Phase: Phase 2 Status: Recruiting
Date: 2024-06-14

View More

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
CTID: NCT03127215
Phase: Phase 2 Status: Completed
Date: 2024-05-08

SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
CTID: NCT03138161
Phase: Phase 1/Phase 2 Status: Recruiting
Date: 2024-04-18

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
CTID: NCT04794127
Phase: Phase 2 Status: Recruiting
Date: 2024-03-13

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
CTID: NCT03023124
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-02-12

tTF-NGR Randomized Study - STS
CTID: NCT05597917
Phase: Phase 3 Status: Recruiting
Date: 2023-12-22

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
CTID: NCT04067115
Phase: Phase 1/Phase 2 Status: Active, not recruiting
Date: 2023-12-21

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
CTID: NCT04535271
Phase: Phase 2 Status: Recruiting
Date: 2023-11-09

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
CTID: NCT04979442
Phase: Phase 3 Status: Terminated
Date: 2023-10-18

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
CTID: NCT03884972
Phase: Phase 1 Status: Withdrawn
Date: 2023-09-25

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy
CTID: NCT01710176
Phase: Phase 3 Status: Active, not recruiting
Date: 2023-09-13

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
CTID: NCT04305548
Phase: Phase 2 Status: Recruiting
Date: 2023-09-13

Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
CTID: NCT02367924
Phase: Status: Completed
Date: 2023-06-22

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
CTID: NCT02275286
Phase: Phase 1/Phase 2 Status: Recruiting
Date: 2023-05-31

Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas
CTID: NCT05131386
Phase: Phase 2 Status: Recruiting
Date: 2023-03-27

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
CTID: NCT04008238
Phase: N/A Status: Recruiting
Date: 2023-03-03

Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin
CTID: NCT02359474
Phase: Phase 2 Status: Active, not recruiting
Date: 2023-02-28

Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
CTID: NCT03590210
Phase: Phase 2 Status: Completed
Date: 2022-11-08

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
CTID: NCT03074318
Phase: Phase 1/Phase 2 Status: Terminated
Date: 2022-04-29

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
CTID: NCT03690739
Phase: Phase 3 Status: Terminated
Date: 2022-02-24

INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
CTID: NCT01379989
Phase: Phase 3 Status: Completed
Date: 2022-02-09

Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
CTID: NCT02997358
Phase: Phase 3 Status: Completed
Date: 2021-12-30

Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
CTID: NCT02247544
Phase: Phase 2 Status: Completed
Date: 2021-11-01

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
CTID: NCT02825420
Phase: Status: Completed
Date: 2021-10-29

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
CTID: NCT02903004
Phase: Phase 3 Status: Completed
Date: 2021-08-25

Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
CTID: NCT02993705
Phase: Phase 2 Status: Completed
Date: 2021-08-25

Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
CTID: NCT02398058
Phase: Phase 1 Status: Completed
Date: 2021-04-14

Trabectedin Maintenance Post 1st-line in STS
CTID: NCT02929394
Phase: Phase 3 Status: Terminated
Date: 2020-09-02

Pharmacometabolomic of Trabectedin in Soft Tissue Patients
CTID: NCT04394728
Phase: Status: Completed
Date: 2020-05-19

ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
CTID: NCT02194231
Phase: Phase 2 Status: Completed
Date: 2020-01-23

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
CTID: NCT03397186
Phase: Phase 2 Status: Withdrawn
Date: 2019-09-10

Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma
CTID: NCT01303094
Phase: Phase 2 Status: Completed
Date: 2019-05-31

Retrospective Study of Trabectedin in Soft Tissue Sarcomas
CTID: NCT02793050
Phase: Status: Completed
Date: 2019-05-10

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
CTID: NCT01846611
Phase: Phase 3 Status: Completed
Date: 2019-04-01

Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
CTID: NCT03437070
Phase: Phase 1 Status: Withdrawn
Date: 2019-03-18

Trabectedin for Recurrent Grade II/III Meningioma
CTID: NCT02234050
Phase: Phase 2 Status: Completed
Date: 2019-02-28

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
CTID: NCT00070109
Phase: Phase 2 Status: Completed
Date: 2018-09-14

Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma
CTID: NCT02672527
Phase: Phase 3 Status: Completed
Date: 2018-08-16

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
CTID: NCT00569673
Phase: Phase 2 Status: Completed
Date: 2018-07-18

A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
CTID: NCT01692678
Phase: Phase 3 Status: Completed
Date: 2018-07-11

Trabectedin First Line Therapy In Unfit Sarcoma Study
CTID: NCT02066675
Phase: Phase 2 Status: Completed
Date: 2018-04-11

An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
CTID: NCT03446495
Phase: Status: Unknown status
Date: 2018-02-26

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
CTID: NCT00379145
Phase: Phase 2 Status: Completed
Date: 2017-12-12

Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
CTID: NCT02249702
Phase: Phase 2 Status: Completed
Date: 2017-12-06

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
CTID: NCT00210665
Phase: Status: No longer available
Date: 2017-10-10

Tabectedin to Treat Children and Adolescents With Cancer
CTID: NCT01453283
Phase: Phase 1 Status: Completed
Date: 2017-07-02

Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
CTID: NCT02131480
Phase: Phase 2 Status: Completed
Date: 2017-01-26

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
CTID: NCT01343277
Phase: Phase 3 Status: Completed
Date: 2016-08-26

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
CTID: NCT01273493
Phase: Phase 1 Status: Completed
Date: 2016-02-15

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
CTID: NCT00796120
Phase: Phase 3 Status: Complet
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2021-01-12

Phase 2 randomized trial of trabectedin + olaparib vs. trabectedin in advanced, metastatic or unresectable soft tissue sarcoma after failure of standard treatments
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2019-11-12

Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) – MITO 26
CTID: null
Phase: Phase 2 Status: Completed
Date: 2019-07-17

Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced Ovarian cancer relapsing after Platinum-based treatment within Six months)
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2018-10-17

Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
CTID: null
Phase: Phase 2 Status: Completed
Date: 2018-08-31

Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial
CTID: null
Phase: Phase 2 Status: Completed
Date: 2018-03-14

Quality of life in patients with non-adipocyte soft tissue sarcoma under
CTID: null
Phase: Phase 4 Status: Prematurely Ended
Date: 2018-02-28

Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian cancer recurring between 6 and 12 months after platinum based chemotherapy.
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2017-10-20

Comparison of QoL between Trabectedin / PLD and standard platinum-based therapy in patients with platinum sensitive recurrent ovarian, fallopian tube and peritoneal cancer - Intergroup-Study of NOGGO and BNGO
CTID: null
Phase: Phase 4 Status: Prematurely Ended
Date: 2017-09-05

Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma
CTID: null
Phase: Phase 3 Status: Completed, Prematurely Ended
Date: 2017-07-04

Solitary fibrous tumor: phase II study on TRabectedin versus Adriamycin plus DAcarbazine in advanced patients (STRADA)
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2017-05-04

Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in patients with metastatic or unresectable leiomyosarcoma (uterine or soft tissue)
CTID: null
Phase: Phase 3 Status: Ongoing
Date: 2016-08-18

Randomized phase III trial on Trabectedin (ET-743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
CTID: null
Phase: Phase 3 Status: Prematurely Ended, Completed
Date: 2015-12-02

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly trabectedin combined with Metronomic Cyclophosphamide in Patients with Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II study from the French Sarcoma Group.
CTID: null
Phase: Phase 1, Phase 2 Status: Ongoing
Date: 2015-10-19

TRABECTEDIN SINGLE AGENT IN PARTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) PATIENTS: A PROSPECTIVE, PHASE II STUDY
CTID: null
Phase: Phase 2 Status: Prematurely Ended
Date: 2015-07-28

Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2015-05-07

Reintroduction of platinum-based therapy after treatment with trabectedin in patients with relapsed ovarian cancer resistant to platinum
CTID: null
Phase: Phase 2 Status: Completed
Date: 2015-04-01

Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients.
CTID: null
Phase: Phase 1, Phase 2 Status: Ongoing
Date: 2014-11-03

A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma
CTID: null
Phase: Phase 2 Status: Completed
Date: 2014-04-16

SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2013-09-04

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
CTID: null
Phase: Phase 3 Status: Completed
Date: 2013-07-11

ATREUS TRIAL
CTID: null
Phase: Phase 2 Status: Completed
Date: 2013-05-23

Multicenter, randomized, non-comparative, open-label phase II trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in adult women with platinum partially sensitive recurring ovarian cancer.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2012-12-13

Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrie and BRCAness phenotype advanced ovarian cancer patients.
CTID: null
Phase: Phase 2 Status: Completed
Date: 2012-04-05

TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma
CTID: null
Phase: Phase 2, Phase 3 Status: Completed
Date: 2011-12-15

USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-07-03

A Pilot Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in refractory ER-positive metastatic breast cancer
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-04-18

Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG)
CTID: null
Phase: Phase 2 Status: Completed
Date: 2011-03-16

Salvage therapy with trabectidin in metastatic pancreatic adenocarcinoma: a single-arm phase II trial.
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2011-02-03

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer
CTID: null
Phase: Phase 3 Status: Ongoing, GB - no longer in EU/EEA, Completed
Date: 2010-10-20

Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis) en première ligne dans le traitement des patients présentant un léiomyosarcome métastatique (utérin ou des tissus mous) et/ou en rechute inopérable
CTID: null
Phase: Phase 2 Status: Completed
Date: 2010-05-12

A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2010-04-07

Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.
CTID: null
Phase: Phase 1, Phase 2 Status: Ongoing
Date: 2009-07-23

ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES Y/O METASTÁSICOS
CTID: null
Phase: Phase 2 Status: Ongoing, Prematurely Ended
Date: 2009-06-04

A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
CTID: null
Phase: Phase 3 Status: Prematurely Ended, Completed
Date: 2008-10-22

A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
CTID: null
Phase: Phase 1, Phase 2 Status: Completed
Date: 2008-10-20

Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral
CTID: null
Phase: Phase 2 Status: Completed
Date: 2008-08-26

Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis®) in
CTID: null
Phase: Phase 2 Status: Prematurely Ended, Completed
Date: 2007-08-01

A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcoma
CTID: null
Phase: Phase 2 Status: Completed
Date: 2007-07-13

TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY
CTID: null
Phase: Phase 2 Status: Ongoing
Date: 2006-10-06

Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma
CTID: null
Phase: Phase 2 Status: Completed
Date: 2006-08-24

An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.
CTID: null
Phase: Phase 3 Status: Completed
Date: 2005-10-27

A Randomized, Multicenter, Open-label Study of YONDELIS ™ (ET-743
CTID: null
Phase: Phase 2 Status: Completed
Date: 2005-05-13